<DOC>
	<DOCNO>NCT02991768</DOCNO>
	<brief_summary>The purpose study learn use Entocort ( budesonide ) treat diarrhea effective safe kidney transplant patient , allow continue MPA medication .</brief_summary>
	<brief_title>Budesonide Mycophenolic Acid-induced Diarrhea Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Kidney transplant recipient &gt; 3 month posttransplant , No history chronic diarrhea pretransplant , &gt; 3 watery/soft stool transplant least 4 day week without antidiarrheal least 2 week use antidiarrheal least 4 day week &gt; 2 week Subjects least 180mg twice day mycophenolatesodium 250 mg twice day cellcept Diagnosis know colonic disease ( i.e . Crohn 's disease , ulcerative colitis , ischemic colitis , Celiac disease ) , partial colonic resection , small bowel resection , history cholecystectomy , Irritable Bowel Syndrome , fecal Incontinence , Bacterial overgrowth , infectious diarrhea ( c difficle , cryptospora , giardia , isospora , Human Immunodeficiency Virus ) , Cytomegalovirus colitis Subjects recent acute rejection treat high dose steroid Subjects take Boswellia serrata extract , overthecounter herb , cholestyramine , nonsteroidal salicylate ( daily ASA ) Subjects active malignancy , liver cirrhosis , active peptic ulcer disease , know intolerance resistance budesonide , pregnancy , breastfeeding , mental retardation Unable provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>